

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
仲 哲治	内科学講座 リウマチ・膠原病・ アレルギー内科分野	教授	博士(医学)	臨床免疫学 腫瘍学	①Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, Morimoto A, Matsuzaki S, Yokoyama T, Takahashi T, Fujimoto M, Takemori H, Ueda Y, Yoshino K, Morii E, Kimura T, Naka T. LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake. Cancer Res. 2018 Jan 15;78(2):516-527. ②Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Kishimoto T, Mori M, Doki Y, Naka T. SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal squamous cell carcinoma. Cancer Res. 2017 Dec 15;77(24):6975-6986. ③Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T. Leucine-rich α 2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015 May;67(8):2056-60 ④Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, Shinzaki S, Nishikawa T, Ohkawara T, Iwahori K, Ohguro N, Kishimoto T, Naka T. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis. 2010 Apr;69(4):770-4. ⑤Naka T, Narasaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997 Jun 26;387(6636):924-9.
藤本 穰	内科学講座 リウマチ・膠原病・ アレルギー内科分野	准教授	博士(医学)	臨床免疫学	① Fujimoto M, Hosono Y, Serada S, Suzuki Y, Ohkawara T, Murata O, Quick A, Suzuki K, Kaneko Y, Takeuchi T, Naka T. Leucine-rich α 2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Mod Rheumatol. 2023 Dec 23:road112. doi: 10.1093/mr/road112. Online ahead of print. ② Tsukuda TK, Ohnishi H, Fujimoto M, Nakatani Y, Takamatsu K, Naka T, Yokoyama A. Lung CCR6-CXCR3- type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases. Sci Rep. 2022;12(1):19577. ③ Fujimoto M, Matsumoto T, Serada S, Tsujimura Y, Hashimoto S, Yasutomi Y, Naka T. Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis. Sci Rep. 2020;10(1):3384. ④ Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, Kawahata H, Serada S, Naka T. Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-beta-Smad2 signaling in naive helper T cells. Arthritis Res Ther. 2017;19(1):137. ⑤ Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T. Leucine-rich alpha2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2056-60.

細野 祐司	内科学講座 リウマチ・膠原病・ アレルギー内科分野	特任准教授	博士(医学)	臨床免疫学	①Y Hosono, M Watanabe, M Sato et al. Multiple intra-articular injections with adipose-derived stem cells for knee osteoarthritis cause severe arthritis with anti-histone H2B antibody production. Regen Ther. 2023;24:147-153. ②Hosono Y, Ishi A, Sato S et al. New Aspects of Clinical and Immunological Characteristics in Patients with Anti-asparaginyl tRNA synthetase (anti-KS) Autoantibody. Mod Rheumatol. 2023;24:road011. ③Hosono Y, Sie B, Mammen AL et al. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1 γ autoantibodies. Ann Rheum Dis 2022. ④ Hosono Y, Nakashima R, Mimori T et al. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. J Autoimmun. 2017;77:116-122. ⑤ Casal-Dominguez M, Pinal-Fernandez I, Hosono Y, et al; Johns Hopkins Myositis Center Group. The indirect immunofluorescence assay autoantibody profiles of myositis patients without known myositis-specific autoantibodies. Clin Exp Rheumatol. 2021;39:519-524
村田 興則	内科学講座 リウマチ・膠原病・ アレルギー内科分野	講師	博士(医学)	リウマチ・ 膠原病内科学	①Murata O, Suzuki K, Takeuchi T, Kudo A. Incidence and baseline characteristics of relapse or exacerbation in patients with pulmonary sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis. 2021; 38(3)e2021026 ②Murata O, Suzuki K, Sugiura H, Kondo Y, Takeshita M, Yasuoka H, Yamaoka K, Koga K, Morita R, Yoshimura A, Takeuchi T. Thymus variants on imaging in patients with rheumatoid arthritis—Clinical and immunological significance. Rheumatology (Oxford). 2021 Feb 16 ③Murata O, Sasaki N, Sasaki K, Kowada K, Ninomiya Y, Oikawa Y, Kobayashi H, Nakamura Y, Yamauchi K. Detection of cerebral microvascular lesions using 7 T MRI in patients with neuropsychiatric systemic lupus erythematosus. Neuroreport. 2015 Jan 7;26(1):27-32 ④Murata O, Izumi K, Kaneko Y, Yasuoka H, Suzuki K, Matsubara S, Yamaoka K, Takeuchi T. Microscopic polyangiitis diagnosed by muscle specimen: a case report and literature review. Modern Rheumatology Case Reports. 2:2, 181-184 ⑤Sugai M, Murata O, Oikawa H, Katagiri H, Matsumoto A, Nagashima H, Sugai T, Maemondo M. A case of bone marrow involvement in sarcoidosis with crescentic glomerular lesions. Respir Med Case Rep. 2020 Aug 28;31:101202
鈴木 悠地	内科学講座 リウマチ・膠原病・ アレルギー内科分野	特任講師	博士(医学)	肝臓病学 再生医療 分子生物学	①Suzuki Y, Kakisaka K, Sato T, Mikami R, Abe H, Sasaki T, Takikawa Y. Tc-99m GSA scintigraphy within the first 3 days after admission as an early predictor of outcome in severe acute liver injury. Sci Rep. 2021;11:12518. ②Suzuki Y, Kakisaka K, Suzuki A, Takahara T, Sasaki T, Sato T, Yonezawa T, Nitta H, Takikawa Y. A Lille model for predicting the response of severe alcoholic hepatitis to corticosteroid treatment in Japanese patients. Hepatol Res. 2019;49:758-764 ③Sasaki T, Suzuki Y, Kakisaka K, Wang T, Ishida K, Suzuki A, Abe H, Sugai T, Takikawa Y. IL-8 induces transdifferentiation of mature hepatocytes toward the cholangiocyte phenotype. FEBS Open Bio. 2019;9:2105-2116. ④Suzuki Y, Katagiri H, Wang T, Kakisaka K, Kume K, Nishizuka SS, Takikawa Y. Ductular reactions in the liver regeneration process with local inflammation after physical partial hepatectomy. Lab Invest. 2016;96:1211-1222. ⑤2023年度科学研究助成事業(科研費)。 基盤研究 (C) , 研究代表者：鈴木悠地, 研究期間：②2023-2025年度, 動物個体の発生原理を利用した、異種間肝臓作製技術の開発

駒ヶ嶺 正嗣	内科学講座 リウマチ・膠原病・ アレルギー内科分野	特任講師	博士(医学)	リウマチ・ 膠原病内科学	
大河原 知治	内科学講座 リウマチ・膠原病・ アレルギー内科分野	助教	学士（医学）	膠原病内科学	① Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, Naka T. Leucine rich α -2 glycoprotein is a potential urinary biomarker for renal tubular injury. Biochem Biophys Res Commun 2018 Apr 15;498(4):1045-1051. ② Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, Naka T.SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.Gastric Cancer 2018 Nov;21(6):968-976. ③ Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K, Ohkawara T, Fujimoto M, Kishimoto T, Kimura T, Naka T. Intratumoral delivery of an adenoviral vector carrying the SOCS-1 gene enhances Tcell-mediated anti-tumor immunity by suppressing. Molecular Cancer Therapeutics 2018 Sep;17(9):1941-1950. ④ Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Koh M, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanazaki K, Mori M, Doki Y, Naka T.Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer.Oncotarget 2018 Aug 31;9(68):32917-32928. [和文] 1.大河原知治, 仲哲治 サイトカインの生理活性 免疫系 SOCSによる免疫制御 現況と展望 医学のあゆみ(0039-2359) 2004; 別冊サイトカイン-state of arts : 71-74.
舟嶋 英志	内科学講座 リウマチ・膠原病・ アレルギー内科分野	助教	修士（理工学）	分子生物学	① Funajima E, Ito G, Ishiyama E, Ishida K, Ozaki T. Mitochondrial localization of calpain-13 in mouse brain. Biochem Biophys Res Commun. 2022 Jun 18;609:149-155. ② Uchida S, Serada S, Suzuki Y, Funajima E, Kitakami K, Dobashi K, Tamatani S, Sato Y, Beppu T, Ogasawara K, Naka T. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. Neoplasia. 2024 Apr;50:100982. ③ Funauchi M, Serada S, Hiramatsu K, Funajima E, Kanda M, Nagase Y, Nakagawa S, Ohkawara T, Fujimoto M, Suzuki Y, Ueda Y, Kimura T, Naka T. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. Int J Cancer. 2024 Feb 1;154(3):425-433. ④ 舟嶋英志, 紺野真秀, 尾崎拓 日本生化学会東北支部 第87回例会・シンポジウム「カルパイン-13の組織分布、細胞内局在および酵素学的性質」